Drug intelligence / Profile preview

prothrombin complex

Development stage
Unknown
Lead developer
CSL Behring
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Prothrombinex-VF is a human plasma-derived three-factor prothrombin complex concentrate (PCC) manufactured by CSL Behring. It contains concentrated vitamin K-dependent coagulation factors II (prothrombin), IX, and X, along with antithrombin III and heparin sodium, but notably contains minimal amounts of factor VII. It is primarily indicated for the rapid reversal of warfarin-induced anticoagulation (warfarin-associated coagulopathy) in patients experiencing major bleeding or requiring urgent surgery. Additionally, it is used for the treatment and perioperative prophylaxis of bleeding in patients with congenital deficiencies of factors II, IX, or X when specific single-factor concentrates are unavailable. By replenishing these essential components of the coagulation cascade, Prothrombinex-VF restores hemostatic potential and restores the patient's ability to form stable blood clots.

Brand names
Prothrombinex-VF
Other names
3-factor prothrombin complex concentrate3-factor PCC
02

Targets

F2 (Thrombin)F9 (Coagulation Factor IX)ATIII (Antithrombin III)F10 (Factor Xa)F7 (Coagulation Factor VII)F5 (Coagulation Factor V)

Beyond the preview

Go deeper on prothrombin complex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on prothrombin complex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call